Literature DB >> 1459834

Influence of prostacyclin infusion on haemodialysis efficiency and blood cells.

M Kuźniewski1, W Sułowicz.   

Abstract

Dialysis efficiency, platelet and leukocyte counts, as well as malonyldialdehyde (MDA) level and lactate dehydrogenase (LDH) activity in serum were assessed in 10 patients (8 males, 2 females, aged 28-58 years) treated with repeated haemodialysis due to terminal renal failure. Patients were examined twice: during a 4-hour haemodialysis in the presence of heparin as the anticoagulant, and a week later in the course of another haemodialysis combined with infusion of heparin and prostacyclin. Statistically significant lower level of urea at the end of dialysis and significantly higher urea clearance were found during haemodialysis with prostacyclin-heparin infusion in comparison with infusion of heparin alone. As compared with the initial values obtained prior to dialysis, neutropenia and thrombocytopenia were observed during haemodialysis with heparin alone but the counts remained generally unaltered when both prostacyclin and heparin were administered. During and after haemodialysis with heparin and prostacyclin both MDA level and LDH activity were lower than in case of haemodialysis with heparin alone.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1459834     DOI: 10.1007/bf02550125

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  32 in total

1.  Effect of heparin and prostacyclin/heparin infusion on platelet aggregation in hemodialyzed patients.

Authors:  M Kuźniewski; W Sułowicz; Z Hanicki; J Kus; M Nowogrodzka-Zagórska; E Kostka-Trabka; K Bieroń; A Debińska-Kieć
Journal:  Nephron       Date:  1990       Impact factor: 2.847

2.  Heparin-associated thrombocytopenia: observations on the mechanism of platelet aggregation.

Authors:  B Adelman; M Sobel; Y Fujimura; Z M Ruggeri; T S Zimmerman
Journal:  J Lab Clin Med       Date:  1989-02

3.  Heparin opposes prostanoid and non-prostanoid platelet inhibitors by direct enhancement of aggregation.

Authors:  D E MacIntyre; R I Handin; R Rosenberg; E W Salzman
Journal:  Thromb Res       Date:  1981 Apr 1-15       Impact factor: 3.944

4.  Prostacyclin and beraprost sodium as suppressors of activated rat polymorphonuclear leukocytes.

Authors:  M Kainoh; R Imai; T Umetsu; M Hattori; S Nishio
Journal:  Biochem Pharmacol       Date:  1990-02-01       Impact factor: 5.858

5.  Haemostatic changes during dialysis associated with thrombus formation on dialysis membranes.

Authors:  R M Lindsay; C R Prentice; J F Davidson; J A Burton; G P McNicol
Journal:  Br Med J       Date:  1972-11-25

6.  Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent.

Authors:  R M Zusman; R H Rubin; A E Cato; D M Cocchetto; J W Crow; N Tolkoff-Rubin
Journal:  N Engl J Med       Date:  1981-04-16       Impact factor: 91.245

7.  Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation.

Authors:  S Moncada; E A Higgs; J R Vane
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

8.  A study on hemodialysis leukopenia using various dialyzers.

Authors:  J Shin; M Matsuo; S Shinko; Y Fujita; S Inoue; R Sakai; M Nishioka
Journal:  J Dial       Date:  1980

9.  Reduction of dialyzer fibrin deposition with sulphinpyrazone.

Authors:  H F Woods; G Ash; V Parsons; M J Weston
Journal:  Clin Nephrol       Date:  1979-09       Impact factor: 0.975

10.  Heparin and prostacyclin.

Authors:  M Camici; L Evangelisti
Journal:  Angiology       Date:  1989-04       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.